Effects of Cilostazol on Platelet Activation in Coronary Stenting Patients Who Already Treated with Aspirin and Clopidogrel
Open Access
- 30 December 2004
- journal article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 19 (4), 230-236
- https://doi.org/10.3904/kjim.2004.19.4.230
Abstract
A recent study has shown that triple anti-platelet therapy (cilostazol+clopidogrel+aspirin) resulted in a significantly lower restenosis rate after coronary stenting than did conventional therapy (clopidogrel+aspirin). However, the anti-platelet effects of cilostazol, when combined with clopidogrel and aspirin, have not been evaluated. Low dose cilostazol (50 mg/BID) was given to 47 patients who had already been taking clopidogrel (75 mg/day) and aspirin (100 mg/day) for more than 1 month subsequent to coronary stenting due to AMI and unstable angina. Markers of platelet activation, P-selectin and activated GPIIb/IIIa on platelets, were measured at baseline and 2 weeks after cilostazol treatment. We empirically divided patients into tertiles (low, n=16; moderate, n=14; high group, n=17), according to the baseline P-selectin expression. We then performed a comparative assessment of the anti-platelet effects of cilostazol at baseline and after 2 weeks of cilosatzol administration. P-selectin was significantly decreased after 2 weeks of cilostazol treatment in total patients (n=47, 3.2±2.4% to 2.0±1.9%, p=0.03). This inhibition of P-selectin expression was mainly achieved in the moderate and high P-selectin groups (low group; 1.4±0.5 to 1.9±1.3%, p>0.05, moderate group; 2.5±0.3 to 1.3±0.3%, p0.05). Underlying disease, cardiovascular risk factors, concomitant medication including statin, and hsCRP were not related to the degree of P-selectin expression. Our data demonstrated that cilostazol treatment in addition to conventional anti-platelet therapy provides more effective suppression of platelet P-selectin expression in patients with relatively high platelet activity.Keywords
This publication has 36 references indexed in Scilit:
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatmentJournal of the American College of Cardiology, 2004
- Clopidogrel for Coronary StentingCirculation, 2003
- Stent-Induced Expression and Activation of the Leukocyte Integrin Mac-1 Is Associated With Neointimal Thickening and RestenosisCirculation, 2003
- Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet AggregationCirculation, 2003
- Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosisAmerican Heart Journal, 2002
- Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment.JCI Insight, 1997
- Leukocyte activation with platelet adhesion after coronary angioplasty: A mechanism for recurrent disease?Journal of the American College of Cardiology, 1996
- Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent plateletsNature, 1992
- Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-(3-(1-Cyclohexyl-5-tetrazolyl)propoxy)-1,2-dihydro-2-oxoquinoline and related compounds.CHEMICAL & PHARMACEUTICAL BULLETIN, 1983